Jennifer Johnson

Jennifer has fifteen years of research experience in the pharmaceutical industry at GlaxoSmithKline. She has experience in immunoassay development and validation as well as in cell-based assay development, optimization, and small molecule screening for a variety of targets in therapeutic areas such as oncology, obesity, and diabetes. She has contributed to the development and validation of biomarker, PK and immunogenicity assays, both cell based and plate based, under GLP regulations. Jennifer has experience with MSD, ELISA and western analysis.

As a member of the Cancer Biology Department at GSK, she developed and ran cell-based and receptor phosphorylation assays that were critical to the selection and development of Votrient™, an oral angiogenesis inhibitor approved by the US FDA for the treatment of advanced renal cell carcinoma. Jennifer has a B.S. in Biology and an M.S. in Biology/Biotechnology from East Carolina University.